


# Jacob Mandel, M.D.

- Assistant Professor of Neurology  
Baylor College of Medicine



## CONTACT INFORMATION

Jacob Mandel, M.D.  
Baylor Neurology  
Baylor College of Medicine Medical Center, McNair Campus  
7200 Cambridge St., 9th Floor, MS: BCM609  
Houston, Texas 77030

Tel: 713-798-7709  
Fax: 713-798-7709  
Email: mandel@bcm.edu

## SPECIALITY

- Neuro-oncology

## CERTIFICATIONS

- American Board of Psychiatry and Neurology, Neurology
- United Council for Neurologic Subspecialties, Neuro-Oncology

## EDUCATION

- M.D., Rush University Medical College, Chicago, Ill.
- B.S., University of Illinois, Chicago, Ill.
- Internship, Internal Medicine, Ohio State University Medical Center, Columbus, Ohio
- Residency, Neurology, Ohio State University Medical Center, Columbus, Ohio
- Fellowship, Neuro-oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas

## PROFESSIONAL INTERESTS

- Neuro-oncology
- Primary brain tumors
- Paraneoplastic syndromes
- Leptomeningeal disease
- Brain metastasis
- Clinical trials for primary brain tumors
- Venous thromboembolism in malignant brain tumors

## CLINIC APPOINTMENTS

713-798-2273

## CLINIC LOCATION

Baylor Neurology  
Baylor College of Medicine Medical Center, McNair Campus  
7200 Cambridge St., 9th Floor, MS: BCM609  
Houston, Texas 77030

## MEMBERSHIPS

- Member, American Academy of Neurology (AAN)

- Member, American Society of Clinical Oncology (ASCO)
- Member, Society of Neuro-Oncology (SNO)

## JOURNAL PUBLICATIONS

1. Harmanci AS, Boudreau B, Lau S, Hosseingholi Nouri S, Mandel JJ, Lu HC, et al. Aggressive human MenG C meningiomas have a molecular counterpart in canines. *Acta Neuropathol.* 2024;147(1):42. PMID: 38376654.
2. Rogers JL, Wall T, Acquaye-Mallory AA, Boris L, Kim Y, Aldape K, et al. Virtual multi-institutional tumor board: A strategy for personalized diagnoses and management of rare CNS tumors. *J Neurooncol.* 2024;38427131. PMID: 38427131.
3. Dodoo GN, De B, Lee SS, Abi Jaoude J, Vauthey JN, Tzeng CD, et al. Brain metastases from biliary tract cancer: Case series and clinicogenomic analysis. *Oncologist.* 2023;28(4):327-32. PMID: 36715178.
4. Mandel JJ, de Groot JF. External control arms and data analysis methods in nonrandomized trial of patients with glioblastoma. *JAMA Oncol.* 2023;9(7):1006. PMID: 37200018.
5. McDonald MF, Prather LL, Helfer CR, Ludmir EB, Echeverria AE, Yust-Katz S, et al. Prevalence of pathogenic germline variants in adult-type diffuse glioma. *Neurooncol Pract.* 2023;10(5):482-90. PMID: 37720399.
6. Ehrlich AM, Larkin MB, English CW, Shetty A, Gupta M, Nouri SH, et al. Protracted course of chemical meningitis following posterior fossa epidermoid cyst excision - A case report. *Surg Neurol Int.* 2022;13:544. PMID: 36447893.
7. Jackson HN, Hadley CC, Khan AB, Gadot R, Bayley JCt, Shetty A, et al. Racial and socioeconomic disparities in patients with meningioma: A retrospective cohort study. *Neurosurgery.* 2022;90(1):114-23. PMID: 34982878.
8. McDonald MF, Athukuri P, Anand A, Gopakumar S, Jalali A, Patel AJ, et al. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas. *Neurosurg Focus.* 2022;53(6):E16. PMID: 36455273.
9. McDonald MF, Rao G, Mandel JJ. Hypertrophic olfactory degeneration postoperatively following pilocytic astrocytoma resection. *World Neurosurg.* 2022;165:18-9. PMID: 35718276.
10. Pati S, Baid U, Edwards B, Sheller M, Wang SH, Reina GA, et al. Federated learning enables big data for rare cancer boundary detection. *Nat Commun.* 2022;13(1):7346. PMID: 36470898.
11. Reddy S, Flores A, Lee S, Shetty A, Shah D, Heck KA, et al. EWSR1-PATZ1 fusion gene in ependymoma: A report of two adult cases and systematic review of literature. *JCO Precis Oncol.* 2022;6:e2200312. PMID: 36480780.
12. Snyder R, Lee S, Heck K, Mandel JJ, Patel AJ, Jalali A. Hemorrhagic cavum vergae colloid cyst: A presentation of anterograde amnesia without hydrocephalus. *Surg Neurol Int.* 2022;13:148. PMID: 35509582.
13. Strowd RE, Dunbar EM, Gan HK, Kurz S, Jordan JT, Mandel JJ, et al. Practical guidance for telemedicine use in neuro-oncology. *Neurooncol Pract.* 2022;9(2):91-104. PMID: 35371525.
14. Woodford R, Prather L, Helfer C, Davey L, Penas-Prado M, Armstrong T, et al. Malignant melanocytic schwannian tumor and leptomeningeal disease: A case series with a focus on management. *J Neurol Sci.* 2022;438:120291. PMID: 35635863.
15. Alkabie S, Castrodad-Molina R, Heck KA, Mandel J, Hutton GJ. The concurrence of multiple sclerosis and glioblastoma. *Mult Scler Relat Disord.* 2021;50:102877. PMID: 33711579.
16. Benouach-Amiel A, Khasminsky V, Gal O, Weiss T, Fichman S, Kanner AA, et al. Multicentric non-enhancing lesions in glioblastoma: A retrospective study. *J Clin Neurosci.* 2021;85:20-6. PMID: 33581785.
17. Flores A, Gadot R, Noorbhai I, Hall H, Heck KA, Raper DMS, et al. S-100-negative, GNA11 mutation-positive intramedullary meningeal melanocytoma of the thoracic spine: A radiographic challenge and histologic anomaly. *Surg Neurol Int.* 2021;12:315. PMID: 34345456.
18. Gopakumar S, Srinivasan VM, Hadley CC, Anand A, Daou M, Karas PJ, et al. Intracranial solitary fibrous tumor of the skull base: Two cases and systematic review of the literature. *World Neurosurg.* 2021;149:e345-e359. PMID: 33609763.
19. Mandel JJ, Youssef M, Yust-Katz S, Patel AJ, Jalali A, Li Z, et al. IDH mutation status and the development of venous thromboembolism in astrocytoma patients. *J Neurol Sci.* 2021;427:117538. PMID: 34146775.
20. Sapienza LG, Ludwig MS, Mandel JJ, Nguyen DH, Echeverria AE. Could patients benefit from whole-brain radiotherapy with unilateral hippocampus sparing? *Rep Pract Oncol Radiother.* 2021;26(3):454-6. PMID: 34277100.
21. Tscherlichovsky R, Katz LH, Derazne E, Berliner MB, Simchoni M, Levine H, et al. Height in adolescence as a risk factor for glioma subtypes: A nationwide retrospective cohort study of 2.2 million subjects. *Neuro Oncol.* 2021;23(8):1383-92. PMID: 33631004.
22. Ben-Zion Berliner M, Katz LH, Derazne E, Levine H, Keinan-Boker L, Benouach-Amiel A, et al. Height as a risk factor in meningioma: A study of 2 million Israeli adolescents. *BMC Cancer.* 2020;20(1):786. PMID: 32819306.
23. de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O'Brien B, et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of

- immune-suppressive macrophages. *Neuro Oncol.* 2020;22(4):539-49. PMID: 31755915.
24. Gal O, Dudnik E, Rotem O, Finkel I, Peretz I, Zer A, et al. Tyrosine kinase inhibitors as a treatment of symptomatic CNS metastases in oncogene-driven NSCLC. *J Oncol.* 2020;2020:1980891. PMID: 32963526.
25. Gopakumar S, Daou M, Gadot R, Ropper AE, Mandel J. Spinal meningioma in a patient with multiple sclerosis. *Surg Neurol Int.* 2020;11:196. PMID: 32754367.
26. Ludmir EB, Subbiah IM, Mainwaring W, Miller AB, Lin TA, Jethanandani A, et al. Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. *J Geriatr Oncol.* 2020;11(3):451-4. PMID: 31711757.
27. Nam JY, Gilbert A, Cachia D, Mandel J, Fuller GN, Penas-Prado M, et al. Pineal parenchymal tumor of intermediate differentiation: A single-institution experience. *Neurooncol Pract.* 2020;7(6):613-9. PMID: 33312675.
28. Patel RR, Verma V, Miller AB, Lin TA, Jethanandani A, Espinoza AF, et al. Exclusion of patients with brain metastases from cancer clinical trials. *Neuro Oncol.* 2020;22(4):577-9. PMID: 31900480.
29. Soomro Z, Youssef M, Yust-Katz S, Jalali A, Patel AJ, Mandel J. Paraneoplastic syndromes in small cell lung cancer. *J Thorac Dis.* 2020;12(10):6253-63. PMID: 33209464.
30. Torrealba-Acosta G, Mandel J. Hyperostosis frontalis interna diagnosed after a provoked seizure. *BMJ Case Rep.* 2020;13(7). PMID: 32611657.
31. Bayley VJ, Goethe EA, Srinivasan VM, Klisch TJ, Mandel JJ, Patel AJ. Newly-diagnosed optic pathway glioma during pregnancy: A case report. *World Neurosurg.* 2019;127:58-62. PMID: 30878749.
32. Goethe EA, Youssef M, Patel AJ, Jalali A, Goodman JC, Mandel JJ. Recurrent papillary glioneuronal tumor. *World Neurosurg.* 2019;128:127-30. PMID: 31078809.
33. Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, et al. Factors associated with age disparities among cancer clinical trial participants. *JAMA Oncol.* 2019;5(12):1769-73. PMID: 31158272.
34. Ludmir EB, Mandel JJ, McAleer MF, de Groot JF. Disparities along the glioblastoma clinical trials landscape. *Neuro Oncol.* 2019;21(2):285-6. PMID: 30476295.
35. Mandel JJ, Youssef M, Nam J, Patel AJ, Jalali A, Ludmir EB, et al. Effect of health disparities on overall survival of patients with glioblastoma. *J Neurooncol.* 2019;142(2):365-74. PMID: 30671709.
36. Prablek M, Srinivasan VM, Srivatsan A, Holdener S, Oneissi M, Heck KA, et al. Gastrointestinal stromal tumor with intracranial metastasis: Case presentation and systematic review of literature. *BMC Cancer.* 2019;19(1):1119. PMID: 31730471.
37. Youssef M, Ludmir EB, Mandel JJ, Patel AJ, Jalali A, Treiber J, et al. Treatment strategies for glioblastoma in older patients: Age is just a number. *J Neurooncol.* 2019;145(2):357-64. PMID: 31643011.
38. Fellner A, Makranz C, Lotem M, Bokstein F, Taliinsky A, Rosenberg S, et al. Neurologic complications of immune checkpoint inhibitors. *J Neurooncol.* 2018;137(3):601-9. PMID: 29332184.
39. Mandel JJ, Youssef M, Ludmir E, Yust-Katz S, Patel AJ, De Groot JF. Highlighting the need for reliable clinical trials in glioblastoma. *Expert Rev Anticancer Ther.* 2018;18(10):1031-40. PMID: 29973092.
40. Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, et al. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. *Neuro Oncol.* 2018;20(1):113-22. PMID: 29016865.
41. Nascimento FA, Kan P, Sharp L, Mandel JJ. Spinal dural arteriovenous fistula and concomitant intramedullary spinal lesion. *Can J Neurol Sci.* 2018;45(2):238-9. PMID: 29251587.
42. Wagner KM, Mandel JJ, Goodman JC, Gopinath S, Patel AJ. Intracranial Erdheim-Chester Disease mimicking parafalcine meningioma: Report of two cases and review of the literature. *World Neurosurg.* 2018;110:365-70. PMID: 29191545.
43. Beechar VB, Srinivasan VM, Reznik OE, Sen A, Klisch TJ, Ropper AE, et al. Intraventricular Cavernomas of the Third Ventricle: Report of 2 Cases and a Systematic Review of the Literature. *World Neurosurg.* 2017;105:935-43 e3. PMID: 28648908.
44. Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, et al. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. *J Neurooncol.* 2017;135(1):75-81. PMID: 28702781.
45. Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, et al. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. *J Neurooncol.* 2016;129(1):147-54. PMID: 27270908.
46. Mandel JJ, Goethe EA, Patel AJ, Heck K, Hutton GJ. Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. *J Neurol Sci.* 2016;369:51-2. PMID: 27653865.
47. Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, et al. Primary and secondary gliosarcomas: Clinical, molecular and survival characteristics. *J Neurooncol.* 2015;125(2):401-10. PMID: 26354773.
48. Ladha H, Pawar T, Gilbert MR, Mandel J, Conrad C, et al. Wound healing complications in brain tumor patients on Bevacizumab. *J Neurooncol.* 2015;124(3):501-6. PMID: 26298437.
49. Mandel JJ, Tummala S, Woodman KH, Tremont-Lukats I. Delayed imaging abnormalities of neuro-invasive West Nile virus in cancer patients. *J Neurol Sci.* 2015;350(1-2):115-7. PMID: 25702151.

50. Pacheco JM, Goodman JC, Mandel J. Intracranial epithelioid hemangioendothelioma causing subacute loss of vision. *Neurology*. 2015;85(8):735-6. PMID: 26304679.
51. Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, et al. Venous thromboembolism (VTE) and glioblastoma. *J Neurooncol*. 2015;124(1):87-94. PMID: 25985958.
52. de Groot JF, Mandel JJ. Update on anti-angiogenic treatment for malignant gliomas. *Curr Oncol Rep*. 2014;16(4):380. PMID: 24510742.
53. Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, et al. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. *J Neurooncol*. 2014;119(1):135-40. PMID: 24803001.
54. Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. *J Neurol Sci*. 2014;344(1-2):229-31. PMID: 24980937.
55. Mandel JJ, Yust-Katz S, Cachia D, Wu J, Liu D, de Groot JF, et al. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. *J Neurooncol*. 2014;120(3):597-605. PMID: 25168214.

## BOOK CHAPTERS and OTHER PUBLICATIONS

1. Eziokwu AS, Mandel J. Primary brain tumors. In: Worden FP, Mims MP, Chew HK, editors. *Tumor Board Review*. 3rd ed. Springer Publishing Company; 2022. p. 361-380.
2. Youssef M, Beal T, Mandel J. Metabolic and nutritional nervous system dysfunction in cancer patients. In: Newton HB, Malkin MG, editors. *Neurological complications of systemic cancer and antineoplastic therapy*. 2nd ed. New York: Informa Healthcare; 2022. p. 179-194.
3. Mandel JJ, Patel A, Yust-Katz S. Gliomas and pregnancy. In: Tonn J-C, Reardon DA, Rutka JT, Westphal M, editors. *Oncology of CNS tumors*. 3rd ed. Cham, Switzerland: Springer; 2019. p. 737-749.
4. Pham L, Cachia D, Patel A, Mandel JJ. Clinical presentation of spinal oligodendroglomas. In: Paleologos NA, Newton HB, editors. *Oligodendrogloma: Clinical presentation, pathology, molecular biology, imaging, and treatment*. London: Elsevier; 2019. p. 11-22.
5. Mandel J, Kesari S. Targeting aberrant signaling pathways. In: Gunel JM, Piepmeyer JM, Baehring JM, editors. *Malignant brain tumors: State-of-the-art treatment*. Switzerland: Springer; 2017. p. 133-150.
6. Mandel J. Neuro-oncology. In: Kass JS, Mizrahi EM, editors. *Neurology secrets*. 6th ed. Philadelphia: Elsevier; 2016. p. 265-275.
7. Newton HB, Mandel JJ. Brain tumor: Meningioma. In: Lynn DJ, Newton HB, Rae-Grant AD, editors. *The 5-minute neurology consult*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 98-99.
8. Newton HB, Mandel JJ. Brain tumor: Metastasis. In: Lynn DJ, Newton HB, Rae-Grant AD, editors. *The 5-minute neurology consult*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 100-101.
9. Newton HB, Mandel JJ. Neurological syndromes and miscellaneous diseases. In: Lynn DJ, Newton HB, Rae-Grant AD, editors. *The 5-minute neurology consult*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 443-452.
10. Newton HB, Mandel JJ. Spinal cord tumor: Ependymoma. In: Lynn DJ, Newton HB, Rae-Grant AD, editors. *The 5-minute neurology consult*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 380-381.
11. Newton HB, Mandel JJ. Spinal cord tumor: Meningioma. In: Lynn DJ, Newton HB, Rae-Grant AD, editors. *The 5-minute neurology consult*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 382-383.

## POSTER and PLATFORM PRESENTATIONS

1. McDonald MF, Prather LL, Helper CR, Ludmir EB, Echeverria AE, Patel AJ, et al. Pathogenic germline mutations in glioma patients. Presented at the Society of Neuro-Oncology (SNO), 27<sup>th</sup> Annual Scientific Meeting and Education Day in Tampa, Fla. (Nov. 16-20, 2022).
2. Rogers J, Acquaye A, Ikiddeh-Barnes U, Benson K, Boris L, Akindona F, et al. An innovative virtual multi-institutional, multidisciplinary neuro-oncology tumor board: The NIH-NOB experience during the COVID-19 pandemic. *Neuro Oncol*. 2021;23(Suppl 6):111.
3. Mandel J, Youssef M, Yust-Katz S, Patel A, Jalali A, Ludmir E, et al. IDH mutation status and the development of venous thromboembolism in astrocytoma patients. *Neuro Oncol*. 2020;22(Suppl 2):125.
4. Mandel J, Youssef M, Ludmir E, Patel A, Jalali A, Treiber J, et al. Treatment strategies for glioblastoma in older patients: Age is just a number. *Neurology*. 2020;94(15 Suppl):2612.
5. Mandel J, Youssef M, Yust-Katz S, Patel A, Jalali A, Wu J, et al. Examining the impact of isocitrate dehydrogenase (IDH) gene status on the development of venous thromboembolism in glioma patients. *Neurology*. 2020;94(15 Suppl):2651.
6. Mandel J, Youssef M, Nam J, Patel A, Liu D, Wu J, et al. Effect of health disparities on overall survival of patients with glioblastoma. *Neuro Oncol*. 2018;20(Suppl 6):81.
7. De Groot JF, Penas-Prado M, Mandel JJ, O'Brien BJ, Weathers S-PS, Zhou S, et al. Window-of-opportunity

clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. Presented at the American Society of Clinical Oncology (ASCO), 54<sup>th</sup> Annual Meeting in Chicago, Ill. (June 1-5, 2018).

8. Mandel J, Youssef M, Nam JY, Wu J, Liu DD, Bondy M, et al. Effect of health disparities on overall survival of patients with glioblastoma. *Neurology*. 2018;90(15 Suppl):P6.157.
9. Nascimento F, Kan P, Sharp L, Mandel J. Spinal dural arteriovenous fistula and concomitant intramedullary spinal lesion. *Neurology*. 2018;90(15 Suppl):P6.122.
10. Yuan D, Nascimento F, Woc-Colburn L, Foroozan R, Mandel J. Vision impairment and papilledema as the initial manifestation of neurosyphilis in a young immunocompetent patient. *Neurology*. 2018;90(15 Suppl):P5.130.
11. Mandel J, Cachia D, Liu DD, Aldape K, Fuller G, De Groot J. Impact of IDH-1 mutation status on outcome in clinical trials for recurrent glioblastoma. *Neurology*. 2016;86(Meeting Abstracts 1):P5.255.
12. Mandel JJ, Cachia D, Liu DD, Aldape KD, Fuller G, De Groot JF. IDH1 mutation status and outcome in clinical trials for recurrent glioblastoma. *J Clin Oncol* 33, 2015 (suppl; abstr 2073)
13. Pawar T, Ladha H, Mandel J, Gilbert M, O'Brien B, Hamza M, et al. Adverse effects of bevacizumab in brain tumor patients. *Neuro Oncol*. 2014;16(suppl 5):v49.
14. Yust-Katz S, Mandel J, Ying Y, Wu J, Courtney C, Ladha H, et al. Venous thromboembolism (VTE) and glioblastoma. *Neuro Oncol*. 2014;16(suppl 5):v212.
15. Mandel J, Webre CC, Shonka NA, Yung WK, De Groot J. Improved progression free survival in 1p/19q co-deleted anaplastic oligodendrogloma treated with both chemotherapy and radiation therapy at diagnosis. *Neurology*. 2014;82(Meeting Abstracts 1):S22.006. [Platform Presentation]
16. Hamza M, O'Brien B, Mandel J, de Groot J. Survival outcomes of patients with recurrent anaplastic glioma treated with bevacizumab. *Neuro Oncol*. 2013;15(suppl 3):iii110-1.
17. Mandel J, Yust-Katz S, de Groot J, Yung A, Gilbert M. Glioblastoma and leptomeningeal dissemination. *Neuro Oncol*. 2013;15(suppl 3):iii119-20.
18. Hamza MA, Mandel J, Conrad CA, Gilbert MR, Yung WKA, Puduvalli VK, et al. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. *J Clin Oncol*. 2013;31(May 20 suppl):2042.
19. Mandel J, Tremont-Lukats I, Tummala S. Tosedostat and posterior reversible encephalopathy syndrome (PRES). *J Neurol*. 2013;260 (suppl 1):S25-6. [Oral Presentation]
20. Mandel J, Woodman K, Tummala S, Tremont-Lukats I. Severe neurological disability in cancer patients acutely infected with the West Nile virus (WNV). *J Neurol*. 2013;260 (suppl 1):S171.
21. Mandel J, Oas J. Sporadic CJD (VV2 Type) presenting with central vestibular abnormalities. *Neurology*. 2012;78(Meeting Abstracts 1):P03.259.
22. Mandel J, Quick A, Lawson V. Early predictors of progression in idiopathic sensory neuropathy. *Neurology*. 2012;78(Meeting Abstracts 1):P03.209.